Christopher M. Hartshorn PhD

Dr. Christopher M. Hartshorn serves as a program director in NCI's Alliance for Nanotechnology in Cancer program. In this role, he manages the nanotechnology research projects, evaluates the effectiveness of the Alliance programs, and maintains the proper stewardship over federally funded research. He serves as a technical expert to Alliance members, acts as senior editor/author on strategic Alliance documents, and participates in the development and direction of new research initiatives.

Prior to joining the NSDB, Dr. Hartshorn worked for the National Institute of Standards and Technology (NIST) on the research and development of novel high-speed non-invasive nonlinear optical imaging modalities for tumor histopathology as well as for in situ materials and pharmaceutical characterization. In addition to his research, he co-founded and led the NIST Material Measurement Laboratory Post-doctoral Association and served on the Washington Editorial Review Board.

Dr. Hartshorn earned his Ph.D. in Physical Chemistry from Washington State University where his research studies focused on modeling the physical effects of nanomaterials at biological interfaces, development of nanoparticle-DNA oligomer conjugates for the single-molecule measurement of HIV-RT binding kinetics, and was part of an interdisciplinary team developing a multi-antigen biosensor. Prior to his graduate work, he co-authored the collaborative discovery of the modulus-density scaling behavior and framework architecture for nanoporous silicates. He earned his Bachelor of Science degree's in Chemistry and Biology from the University of New Mexico.

Over his academic and research career, Dr. Hartshorn has co-authored many peer-reviewed publications including several in Nature journals within the disciplines of nanomaterials, photonics, and biology as well as co-authoring several funded grants and book chapters. He has been the recipient of two national fellowships, an invited speaker for many conferences, and is a member of Sigma Xi and the American Chemical Society.